ARTICLE SUMMARY:
Edwards Lifesciences’ deals highlight the complexity and uncertainty of the emerging transcatheter mitral heart valve market, demonstrating that no two valve markets are alike.
In the last few years, we have seen structural heart disease go from a relatively sleepy, slow growth technology backwater, defined largely by incremental innovations, to the next hot clinical space, marked by truly disruptive product breakthroughs.
